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Abstract 
Response criteria represent the standard by which the efficacy of therapeutic agents is de-
t e r m i n e d   i n   c a n c e r   t r i a l s .   T h e   m o s t   w i d e l y   u s e d   c r i t e r i a   a r e   b a s e d   o n   t h e   a n a t o m i c   m e a-
surement of solid tumors. Because bone metastases are typically located in irregularly shaped 
bones and are difficult to measure with rulers, they have been previously considered un-
measurable disease. New developments in cancer response criteria have increased awareness 
of the importance of the response of bone metastases to therapy. The recently updated 
Response Evaluation Criteria in Solid Tumors (RECIST 1.1) now consider bone metastases 
with soft tissue masses >   1 0   m m   t o   b e   m e a s u r a b l e   d i s e a s e .   R e s p o n s e   c r i t e r i a   s p e c i f i c   t o   b o n e  
metastases have been developed at The University of Texas MD Anderson Cancer Center 
(MDA criteria) and can be used to assess therapeutic response in numerous types of bone 
metastases. Functional imaging criteria, such as the recently developed Positron Emission 
T o m o g r a p h y   R e s p o n s e   C r i t e r i a   i n   S o l i d   T u m o r s   ( P E R C I S T )   a l l o w   r e s p o n s e   t o   b e   m e a s u r e d   i n  
the absence of anatomic change through assessment of metabolic activity. As monitoring 
tumor response of bone metastases becomes more important in the management of cancer, 
so does the demand on radiologists and nuclear medicine physicians for accurate interpre-
tation of the behavior of these lesions. This article reviews anatomic, bone, and metabolic 
response criteria, providing illustrations for the interpretation of therapy-induced change in 
bone metastases.  
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Introduction 
An estimated 569,490 Americans are expected to 
d i e   o f   c a n c e r   i n   2 0 1 0 ,   a c c o u n t i n g   f o r   a p p r o x i m a t e l y  
25% of the overall mortality (1). Bone metastases are a 
c o m m o n   m a n i f e s t a t i o n   o f   a d v a n c e d   d i s e a s e   w i t h   a u-
topsy studies showing an incidence of 33-36% in pa-
tients with lung cancer (2, 3), 68% in prostate cancer 
(3), and 73% in breast cancer (2, 3). While many pa-
tients  receive  therapy  at  major  cancer  centers,  nu-
merous  other  patients  choose  local  or  regional  hos-
pitals, and most imaging studies include the skeleton 
secondarily  if  not  primarily  (e.g. chest  radiography, 
body  computed  tomography  [CT]).  Thus,  the  ap-
pearance and behavior of bone metastases can be de-
t e c t e d   o n   a   w i d e   v a r i e t y   o f   i m a g i n g   s t u d i e s   t h a t   a r e  
performed for many different indications. 
Response  criteria  represent  the  standard  by 
which  the  efficacy of  new  therapeutic  agents  is  de-
termined  in  cancer  treatment  trials.  The  most  com-
monly used set of criteria is the Response Evaluation 
Criteria in Solid Tumors (RECIST). These and similar Journal of Cancer 2010, 1 
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anatomic criteria focus predominantly on the physical 
measurement of solid tumors. Disease that is not eas-
i l y   m e a s u r a b l e   w i t h   a   r u l e r   o r   c a l i p e r s ,   s u c h   a s   m o s t  
bone  metastases,  is  designated  as  unmeasurable. 
Cancer patients with no measurable disease (e.g. in-
dividuals  with  bone-only  metastases  following  the 
resection of a primary tumor) are often ineligible for 
clinical trials, which may be the only available source 
of therapy. Therefore, the absence of measurable tu-
m o r s   c a n   s i g n i f i c a n t l y   a f f e c t   p a t i e n t   d i s e a s e   m a n-
agement. This article reviews anatomic (RECIST 1.1), 
bone (MD Anderson [MDA]), and metabolic (Positron 
Emission  Tomography  Response  Criteria  in  Solid 
T u m o r s   [ P E R C I S T ] )   c a n c e r   r e s p o n s e   c r i t e r i a ,   w i t h   a  
focus on the developing role of bone metastases and 
the  interpretation  of  the  treatment  response  of  bone 
metastases seen on imaging studies. 
RECIST 1.1 
Change  in  tumor  size  following  therapy,  also 
known as objective response (4, 5), is a robust indica-
t o r   o f   o u t c o m e   i n   t h e   t r e a t m e n t   o f   n u m e r o u s   s o l i d  
tumors  (6-9)  and  forms  the  basis  for  anatomic  re-
sponse criteria. RECIST (10), updated to RECIST 1.1 in 
2009 (11), was designed to standardize the assessment 
of therapeutic response to allow meaningful compar-
ison of drug efficacy among individuals in the same 
study and across different studies (12, 13). RECIST 1.1 
s p e c i f i e s   t h a t   u p   t o   5   t a r g e t   l e s i o n s ,   r e p r e s e n t i n g   a l l  
affected organ systems but with no more than 2 target 
lesions  per  organ,  be  selected  for  measurement 
t h r o u g h o u t   t h e   c o u r s e   o f   a   t h e r a p e u t i c   t r i a l .   T o   b e  
considered as target lesions, at baseline nodules must 
measure ≥ 10 mm on CT (or twice the slice thickness if 
the interval i s   >   5   m m ) ,   t h e   s h o r t   a x e s   o f   l y m p h   n o d e s  
must measure ≥ 15 mm on CT (recommended slice 
thickness is < 5   m m ) ,   p a l p a b l e   m a s s e s   m u s t   b e   ≥   1 0  
m m   a s   m e a s u r e d   w i t h   c a l i p e r s ;   a n d   l u n g   l e s i o n s   m u s t  
b e   ≥   2 0   m m ,   c l e a r l y   d e l i n e a t e d ,   a n d   s u r r o u n d e d   b y  
lung parenchyma o n   c h e s t   r a d i o g r a p h s .   L e s i o n s   m a y  
b e   m e a s u r e d   u s i n g   C T   o r   magnetic resonance imaging 
( M R I ) ,   b u t   C T   i s   p r e f e r r e d   i n   m o s t   s i t u a t i o n s   b e c a u s e  
of the variability of MRI scan parameters. Measure-
ments made using ultrasonography are not acceptable 
because of operator dependency and lack of objective 
reproducibility. 
A c c o r d i n g   t o   R E C I S T   1 . 1 ,   d r u g   e f f i c a c y   i s   p r i-
marily determined by the sum of the measurements of 
the  greatest  longitudinal  dimension  of  each  target 
lesion.  One of  the  differences  between  RECIST and 
RECIST  1.1  is  that  bone  metastases  with  soft  tissue 
m a s s e s   m e a s u r i n g   ≥   1 0   m m   a r e   n o w   a c c e p t e d   a s   t a r-
g e t   l e s i o n s .   T h e   s o f t   t i s s u e   c o m p o n e n t   i s   t o   b e   m e a s-
ured  in  an  identical  manner  to  that  used  for  other 
target lesions (Fig. 1). Measurements are to be made in 
the plane of acquisition (typically axial for CT unless 
isotropic reconstructions are performed). The largest 
lesions  are  preferred  if  they  are  clearly  and  repro-
ducibly measurable (e.g. the largest well-defined le-
sion is preferred over larger, ill-defined lesions), and 
no previously irradiated lesion is eligible as a target 
lesion unless it demonstrates progression after irradi-
ation. Therefore, a careful search of the medical record 
for  previous  therapeutic  radiation  exposure  is  indi-
c a t e d   p r i o r   t o   t h e   s e l e ction of a bone metastasis as a 
target lesion. 
RECIST 1.1 states that CT is “the best currently 
available and reproducible method to measure lesions 
selected for response assessment” (11). However, MRI 
h a s   b e e n   s h o w n   s u p e r i o r   t o   C T  in delineating the ex-
t e n t   o f   p r i m a r y   b o n e   t u m o r s   ( w h i c h   a r e   s i m i l a r   t o  
t a r g e t   b o n e   l e s i o n s   b e c a u s e   t h e y   t y p i c a l l y   p r o d u c e  
l a r g e   s o f t   t i s s u e   m a s s e s )   a n d   t h e i r   r e l a t i o n s h i p   t o   a d-
jacent  structures  (14,  15).   T h e   v a l u e   o f   t h e   h i g h   s o f t  
tissue  contrast  resolution  o f   M R I   w a s   s h o w n   i n   a  
p r o s p e c t i v e   s t u d y   c o m p a r i n g   M R I   a n d   C T   f o r   t h e   d e-
tection of locally recurrent t u m o r s   i n   4 9   p a t i e n t s   f o l-
lowing the resection of musculoskeletal malignancies 
(16). In the  33  biopsy-proven locally recurrent tumor 
nodules,  MRI  demonstrated  sensitivity,  specificity, 
and accuracy of 82.5%, 96.3%, and 92.6%, respectively; 
CT  values  for  sensitivity,  specificity,  and  accuracy 
were 57.5%, 96.3%, and 85.0%, respectively. MRI scans 
with and without the use of intravenous gadolinium 
contrast can be considered for the follow-u p   o f   m e a-
surable  bone  lesions.  RECIST  1.1  specifies  contrast 
administration for both MRI and CT scans. 
The 4   r e s p o n s e   c a t e g o r i e s   i n c l u d e d   i n   R E C I S T   1 . 1  
are  complete  response  (CR),  partial  response  (PR), 
progressive disease (PD), and stable disease (SD) (Ta-
ble 1). CR is defined as the disappearance of all target 
lesions and reduction of the short a x e s   o f   t a r g e t   l y m p h  
n o d e s   t o   <   1 0   m m .  Fludeoxyglucose F18 (FDG)  posi-
tron emission tomography (PET) can be used in place 
o f   b i o p s y   t o   v e r i f y   C R   w h e n   a   r e s i d u a l   m a s s   i s  
thought to represent scarring or fibrosis. T h e   P R   c a t-
egory requires a decrease in the sum of the diameters 
of all target lesions by ≥ 30%; the patient’s baseline 
sum of these diameters is the reference standard. PD 
requires an increase of ≥ 20% (with at least a 5-mm 
increase) in the sum of target lesion diameters; again, 
the patient’s smallest recorded sum of these diameters 
is  the  reference  standard.  Additionally,  the  interval 
development of a malignant FDG uptake pattern  is 
considered an indicator of PD unless it corresponds to 
an anatomically stable lesion. The metastasis is to be 
confirmed on contemporaneous or follow-up CT (Fig. 
2 ) .   T h e   S D   c a t e g o r y   i n c l u d e s   a l l   p a t i e n t s   w h o s e   d i s-Journal of Cancer 2010, 1 
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ease  activity  does  not  meet  the  requirements  of  the 
other 3 categories u s i n g   t h e   s m a l l e s t   p r e v i o u s   s u m   o f  
lesion diameters as the reference standard. 
RECIST 1.1 designates numerous lesions as un-
measurable.  These  include  small  tumors  (nodules 
with a short-a x i s   d i m e n s i o n   <   1 0   m m ) ,   l e p t o m e n i n-
geal  disease,  lymphangitic  spread,  inflammatory 
breast disease, pericardial/pleural effusions, palpable 
abdominal  masses/organomegaly  not  reproducible 
on imaging studies, lesions surrounded by postradia-
tion  scar  tissue,  and  bone  metastases  without  soft 
t i s s u e   m a s s e s   m e a s u r i n g   ≥   1 0   m m   ( t h e   l a r g e   m a j o r i t y  
of bone metastases). While no focus of unmeasurable 
d i s e a s e   c a n   b e   u s e d   a s   a   t a r g e t   l e s i o n ,   t h e   p r o g r e s s i o n  
o f   s u c h   t u m o r s   c a n   h a v e   a n   e f f e c t   o n   t h e  RECIST  re-
sponse assessment under the designation of unequi-
vocal  progression  of  nontarget  lesions.  In  general, 
p r o g r e s s i o n   o f   n o n t a r g e t   l e s i o n s   i s   t o   b e   e s t i m a t e d   a s   a  
2 0 %   i n c r e a s e   i n   t h e   s u m   o f   t h e   g r e a t e s t   t u m o r   d i a m e-
ters,  which  is calculated to be a 73% increase in vo-
l u m e ,   b y   t h e   a u t h o r s   o f   t h e   R E C I S T   c r i t e r i a   (11). 
Therefore,  frank  progression  of  bone  metastases  on 
any imaging modality can contribute to the classifica-
tion of overall patient response through the designa-
tion of unequivocal progression (Fig. 3). 
 
 
Figure 1. Measurement of disease progression using the RECIST 1.1 criteria. (a) Axial CT of the pelvis and abdomen of a 
patient with renal cell carcinoma demonstrates a bone metastasis in the left inferior pubic ramus. The soft tissue component 
i s   >   1 0   m m ,  and (b) the short-axis diameter of the left retroperitoneal lymph node metastasis is >15 mm; both are con-
sidered measurable according to RECIST 1.1. The sum of the longest diameters is used to assess tumor response. (c) The 
b o n e   m e t a s t a s i s   h a s   i n c r e a s e d   f r o m   2 5 . 2   m m   t o   6 1 . 5   m m ,   a n d   (d) t h e   n o d a l   m e t a s t a s i s   h a s   i n c r e a s e d   f r o m   2 4 . 2   m m   t o   3 2 . 9  
mm. The sum of the 2 lesions at the first time point is 49.4 mm, and the sum at the second time point is 94.4 mm. This 
increase of 91% exceeds the required > 20% increase that is necessary to qualify for the progressive disease category.  
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Table 1 Response Evaluation Criteria in Solid Tumors (RECIST 1.1)* 
Response category  Criteria 
Complete response  Disappearance of all target lesions 
Reduction in short axis of target lymph nodes to < 10 mm 
Partial response  Decrease in target lesion diameter sum > 30%† 
Progressive disease  Increase in target lesion diameter sum > 20%‡ 
> 5 mm increase in target lesion diameter sum 
New, malignant FDG uptake in the absence of other indications of progressive disease or an anatomi-
cally stable lesion, and confirmed on contemporaneous or follow-up CT 
Unequivocal progression of nontarget lesions 
Stable disease  Does not meet other criteria‡ 
*Measurements are based on the sum of the unidimensional measurement of the greatest diameter of a maximum 5 lesions. 
†Reference standard: baseline sum. 
‡Reference standard: smallest recorded sum. 
Table modified from Eisenhauer et al. (11). 
 
 
 
 
 
Figure 2. U s e   o f   F D G   P E T / C T   a c c o r d i n g   t o   t h e   R E C I S T   1 . 1   c r i t e r i a .   (a) C T   o f   t h e   L 3   v e r t e b r a   i n   a   p a t i e n t   w i t h   b r e a s t  
cancer reveals no indication of bone metastases. (b) Focal FDG uptake indicative of metastatic disease is present on 
PET/CT. The interval development of an FDG-avid focus, in the absence of any other indication of disease progression, is 
considered progressive disease under RECIST 1.1 unless it corresponds to a pre-existing, anatomically stable abnormality. 
RECIST 1.1 specifies that the metastasis is to be confirmed on a follow-up CT.(c) A fat-saturated T1-weighted axial MRI 
image obtained following the administration of intravenous contrast was available and reveals an enhancing lesion in the 
location of FDG uptake (arrowheads), confirming the presence of the metastasis. 
 
 
 
 
 
Figure 3. Unequivocal progression of unmeasurable disease according to the RECIST 1.1 criteria. (a)T1-weighte d   a x i a l   M R I  
of a patient with renal cell carcinoma demonstrates a small metastasis in the marrow cavity of the distal phalanx of the left 
great toe (arrow). Bone disease without a soft tissue mass > 1 0   m m   i s  considered unmeasurable disease under RECIST 1.1. 
(b) Eight months later, the metastasis has markedly enlarged, representing unequivocal progression of unmeasurable dis-
ease. (c) A frontal radiograph of the foot demonstrates complete cortical lysis of the distal phalanx. The toenail is evident 
(arrowhead). Periarticular osteopenia is likely secondary to disuse.  
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MDA Criteria 
The field of oncology has seen several genera-
tions  of  cancer  response  criteria.  The  International 
Union  Against  Cancer  (UICC)  (17)  and  the  World 
Health Organization (WHO) (4) published criteria in 
1977  and  1979,  respectively.  While  at  the  time 
representing the most sophisticated attempts to stan-
d a r d i z e   t h e   e v a l u a t i o n   o f   t u m o r   r e s p o n s e ,   t h e s e   c r i t e-
ria were published before the widespread availability 
o f   C T .   B o t h   s e t s   o f   c r i t e r i a ,   w h i c h   h a v e   b e e n   l a r g e l y  
supplanted by RECIST and RECIST 1.1, consider bone 
metastases to be measurable disease. Additionally, the 
WHO  criteria  include  radiograph-based  guidelines 
for  the  interpretation  of  bone  metastases;  however, 
these  guidelines  were  not  adopted  by  RECIST  or 
R E C I S T   1 . 1 .   T h e   r e s u l t a n t   v o i d   r e g a r d i n g   t h e   e v a l u a-
t i o n   o f   b o n e   m e t a s t a s e s   l e d   t o   t h e   d e velopment  of 
bone-specific  response  criteria  at  The  University  of 
Texas MD Anderson Cancer Center in 2004 (18).  The 
MDA criteria updated the UICC and WHO bone re-
sponse criteria by expanding radiographic assessment 
and incorporating both CT and MRI. 
The MDA criteria divide response into 4 stan-
dard categories (CR, PR, PD, and SD) and include 
quantitative and qualitative assessments of the beha-
v i o r   o f   b o n e   m e t a s t a s e s   ( T a b l e   2 ) .   P R   i s   d e f i n e d   a s   a  
decrease  of ≥  50% i n   t h e   s u m   o f   t h e   p e r p e n d i c u l a r  
measurements of any lesion and PD as an increase of 
≥ 25% in this sum. 
Table 2 MD Anderson (MDA) criteria* 
Response category  Criteria 
Complete response  Complete sclerotic fill-in of lytic lesions on XR or CT 
Normalization of bone density on XR or CT 
Normalization of signal intensity on MRI 
Normalization of tracer uptake on SS 
Partial response  Development of a sclerotic rim or partial sclerotic fill-in of lytic lesions on XR or CT. 
Osteoblastic flare - Interval visualization of lesions with sclerotic rims or new sclerotic lesions in the setting of 
other signs of PR and absence of progressive bony disease  
≥ 50% decrease in measurable lesions on XR, CT, or MRI 
≥ 50% subjective decrease in the size of ill-defined lesions on XR, CT, or MRI 
≥ 50% subjective decrease in tracer uptake on SS 
Progressive disease  > 25% increase in size of measurable lesions on XR, CT, or MRI 
> 25% subjective increase in the size of ill-defined lesions on XR, CT, or MRI 
> 25% subjective increase in tracer uptake on SS 
New bone metastases 
Stable disease  No change 
< 25% increase or < 50% decrease in size of measurable lesions 
< 25% subjective increase or < 50% subjective decrease in size of ill-defined lesions 
No new bone metastases 
*Measurements are based on the sum of a perpendicular, bidimensional measurement of the greatest diameters of each individual lesion. 
Abbreviations: XR, radiography; CT, computed tomography; SS, skeletal scintigraphy; MRI, magnetic resonance imaging. 
Table modified from Hamaoka et al. (18). 
 
A c c o r d i n g   t o   t h e   M D A   c r i t e r i a ,   C R   i s   defined as 
complete  sclerotic  fill-in  of  lytic  lesions  on  radio-
grap h s   o r   C T ,   t h e   r e s t o r a t i o n   o f   n o r m a l   b o n e   d e n s i t y  
on radiography or CT, the disappearance of abnormal 
tracer  uptake  on  skeletal  scintigraphy  (SS),  and  the 
normalization of signal intensity on   M R I   ( F i g .   4 ). The 
PR category includes the development of a sclerotic 
rim (Fig. 5) or partial (rather than complete) sclerotic 
fill-i n   o f   l y t i c   m e t a s t a s e s   o n   r a d i o g r a p h y   o r   C T ;   ≥   5 0 %  
decrease  in  t h e   s u m   o f   t h e   p e r p e n d i c u l a r   m e a s u r e-
ments  of  measurable  lesions on radiography, CT, or 
MRI (Fig. 6); ≥ 50% subjective decrease in the sum of 
the  perpendicular  measurements  of  unmeasurable 
(ill-defined)  lytic  or  blastic  lesions  on  radiography, 
C T ,   o r   M R I   t h a t   c a n n o t   b e   a c c o u n t e d   f o r   b y   c h a n g e s   i n  
obliquity  or  slice  placement;  and  ≥  50%  subjective 
decrease in tracer uptake on SS ( F i g .   7 ) . A   c a v e a t   t o   t h e  
PR  designation  involves  the  osteoblastic  flare  phe-
nomenon. Interval visualization of sclerotic lesions or 
lytic lesions with sclerotic rims,   i n   t h e   s e t t i n g   o f  other 
s i g n s   o f   P R ,   d o e s   n o t   i n d i c a t e   d i s e a s e   p r o g r e s s i o n   b u t  
the healing of previously inconspicuous lesions (19). 
O s t e o b l a s t i c   f l a r e   c a n n o t   b e   d i agnosed if any preex-
isting  lesions  show  signs  of  progression  (e.g.  en-
largement of lytic lesions, development of new lytic 
lesions) (Fig. 8). PD is defined as > 25% increase in the 
sum of the perpendicular measurements of any mea-
surable  lesion  on  radiography,  CT,  or  MRI;  >  25% 
subjective  increase  in  the  size  of  unmeasurable 
(ill-d e f i n e d )   l y t i c   o r   b l a s t i c   l e s i o n s   o n   X R ,   C T   o r   M R I  
t h a t   c a n n o t   b e   a c c o u n t e d   f o r   b y   o b l i q u i t y   o r   s l i c e  
placement; > 25% subjective increase in tracer uptake Journal of Cancer 2010, 1 
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on SS; or the development of new metastases. An in-
c r e a s e   i n   t r a c e r   u p t a k e   o n   S S   m a y   n e e d   c o r r e l a t i o n  
with  other  imaging  studies  to  exclude  the  scinti-
graphic  flare  phenomenon,  which  is  typically  seen 
within the first 3 months after therapy. 
Scintigraphic  flare  occurs  when  heal-
ing scl e r o s i s   r e s u l t s   i n   m o r e   t r a c e r   u p t a k e   t h a n   w a s  
c a u s e d   b y   t h e   u ntreated lesion (Fig. 9) (20-24). SD is 
defined as < 25% increase or < 50% decrease in size or 
no change in measurable lesions and no new lesions. 
 
 
Figure  4.  Complete  response  on  MRI 
using the MDA criteria. (a) T1-weighted 
sagittal  MRI  of  the  thoracic  spine  of  a 
patient with breast cancer demonstrates a 
lesion  in  the  T11  vertebral  body  with 
abnormally  low  T1  signal  intensity.  (b) 
Eight years later, the lesion has been re-
placed by normal fat signal (arrow). The 
upper  thoracic  spine  is  slightly  tilted  in 
position  on  the  follow-up  examination. 
The response is complete according to the 
MDA criteria.  
 
 
 
 
 
Figure 5. Partial response on radiographs according to the MDA criteria. (a) A   l y t i c   m e t a s t a s i s   i s   s e e n   i n   t h e   C 7   v e r t e b r a l  
b o d y   o n   C T   i n   a   p a t i e n t   w i t h   b r e a s t   c a n c e r .   (b) Fused P E T / C T   i m a g e   f r o m   t h e   s a m e   e x a m i n a t i o n   d e m o n s t r a t e s   F D G   u p t a k e  
representing active tumor. (c) Five weeks later, the lesion developed a sclerotic rim that resulted in a reduction in the size 
of the lytic area. (d) F u s e d   P E T / C T   i m a g e   f r o m   t h e   s a m e   e x a m i n a t i o n   a s   (c) shows resolution of FDG activity, confirming the 
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Figure  6.  Quantitative measurement of 
PR  using  the  MDA  criteria.  (a) 
T1-weighted sagittal MRI of the thoracic 
spine of a patient with multiple myeloma 
demonstrates a lesion with abnormally low 
T1 signal intensity in the T5 vertebral body. 
(b) Seven months later, fat reconstitution 
occurred  around  the  periphery  of  the 
l e s i o n ,   r e s u l t i n g   i n   a   d e c r e a s e   i n   t h e   s i z e   o f  
the metastasis. The sum of the perpendi-
cular  dimensions  of  the  lesion  has  de-
creased from 27.6 mm to 12.8 mm (a 52% 
reduction in size), qualifying as partial re-
sponse according to the MDA criteria (> 
50% reduction required). The metastasis 
to the severely compressed T6 vertebral 
b o d y   i s   a n   e x a m p l e   o f   a   l e s i o n   t h a t   r e m a i n s  
unmeasurable with anatomic response cri-
teria. 
 
Figure  7. Differentiation of PR from CR 
using the MDA criteria. (a) C T   o f   t h e   T6 
vertebra  i n   a   p a t i e n t   w i t h   b r e a s t   c a n c e r  
demonstrates a mixed lytic/blastic metasta-
sis in the anterior aspect of the vertebral 
body. (b) The lesion shows complete scle-
rotic fill-in 3 months later. In isolation, this 
response  qualifies  as  complete  response 
even though progressive sclerosis may be 
seen on subsequent examinations. (c,  d) 
However,  companion  Tc  99m  methylene 
diphosphonate  (MDP)  bone  scans  show 
improvement but not complete resolution 
of MDP uptake. The patient’s response  is 
therefore considered partial. 
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Figure 8. Osteoblastic flare. (a) T h e   C T   p o r t i o n   o f   a n   F D G   P E T / C T   o f   t h e   p e l v i s  
of a patient with breast cancer shows scattered lytic and blastic metastases in the 
bony pelvis. (b) Fused PET/CT shows significant tracer uptake in the right iliac 
bone and right sacral ala, indicative of metabolically active disease. (c) Nine 
months later, the iliac lesion demonstrates sclerosis (arrow), and 2 round scle-
rotic lesions are now seen in the right sacral ala (arrowheads). In isolation, these 
findings might be representative of disease progression, but lytic lesions in other 
locations (not shown) demonstrated sclerotic fill-in, raising the possibility of an 
osteoblastic flare rather than progressive disease. (d) F u s e d   i m a g e   f r o m   t h e   s a m e  
examination shows marked decrease in metabolic activity, confirming positive 
response to therapy and osteoblastic flare on the CT portion of the examination. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Scintigraphic flare. (a) Numerous bone metastases show tracer uptake on a Tc 99m MDP bone scan in a patient 
with breast cancer. (b) Companion CT examination demonstrates a lytic metastasis in the L1 vertebral body. (c) Six months 
later, the lesions demonstrate increased tracer uptake. (d) Companion CT shows sclerotic fill-in of the lytic lesion, which 
can occur with disease progression or healing. (e, f) Fat-saturated T1-weighted sagittal MRI examinations of the lumbar 
spine obtained (e) 1 month and (f) 2 months after the bone scans show a decrease in the size and/or enhancement of the 
metastases, indicating a positive response to therap y .   I n c i d e n t a l   n o t e   i s   m a d e   o f   i n t e r v a l   i n s u f f i c i e n c y   f r a c t u r e   o f   t h e   s u p e r i o r  
endplate of L4 on (f). The increased MDP uptake on the bone scan (b) was the result of healing sclerosis and representative 
of a scintigraphic flare in a patient undergoing partial response rather than progressive disease.  
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I n   a   s t u d y   c o m p a r i n g   t h e   M D A ,   U I C C ,   a n d  
WHO  criteria  in  41  breast  cancer  patients  with 
bone-o n l y   m e t a s t a s e s ,   t h e   M D A   c r i t e r i a   w e r e   s h o w n  
to  better  differentiate  responders  to  chemotherapy 
f r o m   n o n r e s p o n d e r s   a n d   w e r e   t h e   o n l y   s e t   o f   c r i t e r i a  
to  correspond  to  progression-free  survival  (25).  Ac-
c o r d i n g   t o   t h e   M D A   c r i t e r i a ,   t i m e   t o   d i s e a s e   p r o g r e s-
sion  was  5.5  months  for  nonresponders  and  23.3 
months  for  responders  (P  = 0.025), compared with 
10.4 months and 12.4 months, respectively, according 
to  the  WHO  criteria  (P  =  0.55 ) .   T h e   M D A   c r i t e r i a  
identified nonresponders earlier and better correlated 
with clinical response in the first 2-6 months of ther-
apy than did the WHO criteria. Early signs of disease 
progression are valuable, allowing the halting of in-
effective therapy in a timely fashion and the possible 
substitution of effective therapy. In addition to their 
utility for guiding treatment decisions, the MDA bone 
response criteria closely reflect the behavior of bone 
metastases on radiography and CT and can be used as 
guidelines  for  the  interpretation  of  these  studies 
whether or not a patient is enrolled in a therapeutic 
t r i a l .   T h e   M D A   c r i t e r i a   c a n   b e   c o n s i d e r e d   f o r   u s e   i n  
conjunction with other cancer response criteria or in 
patients with bone-only metastases and no measura-
ble disease. 
PERCIST 
PET has the potential to revolutionize the defini-
t i o n   o f   m e a s u r a b l e   t u m o r s   b e c a u s e   i t   i n t r o d u c e s   i m-
aging  criteria  based  on  function.  The  regular, 
well-defined  tumor  margins  that  are  necessary  for 
reproducible  anatomic  measurements  are  of  lesser 
importance in functional imaging. FDG is a radiola-
beled form of glucose that cannot be metabolized and 
t h e r e f o r e   a c c u m u l a t e s   i n   c e l l s ,   w h i c h   t a k e   u p   t h e   m o-
lecules as if they were normal glucose. Through this 
accumulation,  FDG  activity  acts  as  a  surrogate  for 
glucose metabolism (26). Since many malignancies are 
h i g h l y   m e t a b o l i c   a n d   a c c u m u l a t e   F D G ,   i t   i s   t h e   m o s t  
commonly used PET agent for oncologic indications. 
The following review of the PERCIST criteria includes 
many of the concepts discussed in the source article 
(27). 
Evaluation of tumor response with FDG PET has 
several advantages over anatomically based criteria. 
Some  chemotherapeutic  agents  are  cytostatic  rather 
than cytocidal and therefore do not result in a pro-
found change in tumor size despite their effectiveness 
(28-30), and some malignancies, such as gastrointes-
tinal stromal tumors, do not demonstrate PR through 
a large decrease in size (31). By reflecting change in 
t u m o r   m e t a b o l i s m ,   F D G   P E T   s c a n n i n g   c a n   p r o v i d e   a  
m e t h o d   b y   w h i c h   t u m o r   r e s p o n s e   c a n   b e   m e a s u r e d   i n  
the absence of marked anatomic change (32). A de-
c r e a s e   i n   F D G   u p t a k e   h a s   b e e n   s h o w n   t o   i n d i c a t e  
treatment response and/or improved survival times 
i n   p a t i e n t s   w i t h   s o l i d   t u m o r s   s u c h   a s   b r e a s t   c a n c e r   (33, 
34),  esophageal  cancer  (35-37),  lung  cancer  (38,  39), 
osteosarcoma (40, 41),  and  others (42).   F D G   P E T   h a s  
a l s o   b e e n   s h o w n   t o   p r o v i d e   m o r e   r a p i d   r e s p o n s e   d a t a  
than anatomic measurements (43-45).  FDG  PET/CT 
h a s   a l s o   b e e n   u s e d   t o   s u c c e s s f u l l y   m o d i f y   d i s e a s e  
management (46) by preventing futile thoracotomies 
in patients with lung cancer (47) and  stratifying  pa-
t i e n t s   w i t h   c o l o r e c t a l   c a n c e r   i n t o   s u r g i c a l   v e r s u s   p a l-
liative groups (48). 
Uniformity of measurement and reproducibility 
o f   r e s u l t s   a r e   o f   p a r a m o u n t   i m p o r t a n c e   i n  cancer  re-
s p o n s e   c r i t e r i a   s o   t h a t   d a t a   f r o m   o n e   s t u d y   c a n   b e  
m e a n i n g f u l l y   c o m p a r e d   t o   d a t a   f r o m   o t h e r   s t u d i e s .  
Many acceptable scan acquisition parameters are in 
clinical use, and several previous attempts have been 
m a d e   t o   s t a n d a r d i z e   P E T   f o r   c a n c e r   t r i a l s   t h r o u g h  
guidelines such as those published by the European 
Organization for Research and Treatment of Cancer 
(EORTC)  (49),   t h e   N e t h e r l a n d s   S o c i e t y   o f   N u c l e a r  
Medicine (50), and the National Cancer Institute (51). 
PERCIST, published in the Journal of Nuclear Medicine 
(27), represents the most recent ef f o r t   t o   c r e a t e   s t a n-
dardized  criteria  that  accurately  reflect  response  in 
t h e   l a r g e s t   n u m b e r   o f   m a l i g n a n c i e s .   T h e   P E R C I S T  
c r i t e r i a   u t i l i z e   t h e   c o n c e p t   o f   t u m o r   r e s p o n s e   a s   a  
c o n t i n u o u s   v a r i a b l e .   B e c a u s e   t u m o r   r e s p o n s e   i s   i n h e-
rently  continuous,  discrete  categorization  (e.g.  CR, 
P R ,   P D ,   a n d   S D )   m a y   r e s u l t   i n   t h e   l o s s   o f   i m p o r t a n t  
information (27, 28, 52). Therefore, PERCIST specifies 
t h a t   t h e   p e r c e n t a g e   o f   c h a n g e   i n   m e t a b o l i c   a c t i v i t y  
f r o m   b a s e l i n e   a n d   t h e   n u m b e r   o f   w e e k s   f r o m   t h e   i n-
i t i a t i o n   o f   t h e r a p y   b e   r e c o r d e d   t o   p r o v i d e   a   c o n t i-
nuous plot of tumor activity.  
The  primary  determinant  of  response  using 
PERCIST is the standardized uptake  value  (SUV),  a 
semiquantitative  measure  of  activity  that  is  most 
commonly calculated by dividing the measured tu-
mor  activity  by  injected  dose/body  weight  (53). 
Among  the  many  variants  of  SUV  (e.g.  maximum 
SUV, mean SUV), SU V   c o r r e c t e d   f o r   l e a n   b o d y   m a s s  
( S U L )   w a s   s e l e c t e d   f o r   u s e   w i t h   P E R C I S T   b e c a u s e  
S U L   h a s   b e e n   s h o w n   t o   b e   l e s s   s u s c e p t i b l e   t o   v a r i a-
t i o n s   i n   p a t i e n t   b o d y   w e i g h t   t h a n   t h e   o t h e r   S U V   m e-
trics (54, 55).   P E R C I S T   s p e c i f i e s   t h a t   t h e   S U L   p e a k   i s   t o  
b e   o b t a i n e d   o n   t h e   s i n g l e   m o s t   a c t i v e   l e s i o n   o n   e a c h  
s c a n .   S U L   p e a k   i s   t h e   a v e rage of the activity within a 
spherical region of interest measuring 1.2 cm in di-
ameter (for a volume of 1 cm3) centered at the most 
a c t i v e   p o r t i o n   o f   t h e   t u m o r .   T h e   S U L   p e a k   m a y   b e  
located in a different lesion on a follow-u p   s c a n   b e-Journal of Cancer 2010, 1 
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c a u s e   t h e   c u r r e n t   m o s t  avid lesion is to be measured. 
U s i n g   a   c o n c e p t   s i m i l a r   t o   R E C I S T ,   i t   i s   a l s o   r e c o m-
m e n d e d   t h a t   a   s u m   o f   t h e   a c t i v i t y   o f   u p   t o   5   t a r g e t  
l e s i o n s   ( n o   m o r e   t h a n   2   p e r   o r g a n )   b e   m e a s u r e d   a s   a  
secondary  determinant  of  response.  Future  studies 
will show which of the 2 methods of response deter-
mination most accurately reflects treatment outcome.  
An alternative m e t r i c   t h a t   c a n   b e   u s e d   t o   d e t e r-
mine FDG avidity according to the PERCIST criteria is 
t o t a l   l e s i o n   g l y c o l y s i s   ( T L G ) .   T h i s   i s   a   m e a s u r e   o f   the 
FDG uptake of the entire tumor above a pre-set thre-
shold and is calculated by multiplying the mean SUV 
by  total  tumor  volume  (mL)  (27,  56) TLG  has  been 
tested  in  several  malignancies  and  has  produced 
mi x e d   r e s u l t s   i n   c o m p a r i s o n   t o   S U V  metrics, showing 
a weaker correlation with response in bone metastases 
in breast cancer patients (57) and in sarcomas(41, 58) 
b u t   e q u a l   o r   b e t t e r   i n   e s o p h a g e a l ,   l u n g ,   g a s t r i c   a n d  
rectal cancer (59) (60, 61). PERCIST suggests that SUL 
p e a k   a n d   T L G   c a n   b e   m e a s u r e d   s i m u l t a n e o u s l y   i n  
order to further evaluate the efficacy of TLG. For fur-
t h e r   s p e c i f i c s   r e g a r d i n g   P E T   s c a n n i n g ,   s u c h   a s   i n f o r-
mation regarding patient preparation and scan acqui-
sition, please see the PERCIST source article by Wahl 
et al. (55). 
PERCIST defines 4 response categories (Table 3) 
in addition t o   p l o t t i n g   t u m o r   r e s p o n s e   i n   w e e k s   f r o m  
the initiation of therapy. Complete metabolic response 
is defined as the disappearance of  metabolic  tumor 
activity in target and nontarget lesions. Residual FDG 
uptake can be seen despite effective therapy, possibly 
due  to  macrophage  activity  (62),  and  therefore 
PERCIST  define  complete  metabolic  response  as  a 
d e c r e a s e   i n   t u m o r   S U L   t o   t h e   l e v e l   o f   s u r r o u n ding 
normal  tissue.  Partial metabolic response is defined 
b y   a   d e c l i n e   o f   >   3 0 %   i n   S U L   p e a k   w i t h   a t   least  a 
0.8-unit decline (Fig. 10). Progressive metabolic dis-
e a s e   i n c l u d e s   a n   i n c r e a s e   o f   >   3 0 %   i n   S U L   p e a k   w i t h   a t  
least a 0.8-unit increase, a visible increase in the extent 
o f   F D G   u p t a k e   ( i n c r e a s e   i n   t h e   c o l o r   f i e l d   r e p r e s e n t i n g  
FDG uptake) ,   o r   t h e   d e v e l o p m e n t   o f   n e w   l e s i o n s .  In 
the absence of clear evidence of disease progression 
o n   t h e   f u s e d   C T   i m a g e ,   n e w   F D G -avid foci are to be 
verified on a follow-up scan 1 month after discovery. 
S t a b l e   m e t a b o l i c   d i s e a s e   i s   t h e   a b s e n c e   o f   c h a n g e   o r  
m i l d   c h a n g e s   t h a t   d o   n o t   m e e t   t h e   m i n i m u m   q u a l i f i-
cations  of  the  other  categories.  Anatomic  change  in 
t u m o r   s i z e   r e m a i n s   a n   i m p o r t a n t   f a c t o r   u n d e r  
P E R C I S T   a n d   i s   t o   b e   m e a s u r e d according to RECIST 
1.1. If lesions increase or decrease in size without a 
corresponding change in metabolic activity, disease 
p r o g r e s s i o n   o r   r e s p o n s e   i s   t o   b e   v e r i f i e d   o n   a   f o l-
low-up scan.  
When evaluating the potential role of functional 
imaging modalit i e s   s u c h   a s   P E T ,   t h e   R E C I S T   w o r k i n g  
group decided that there was “not sufficient standar-
dization or evidence to abandon anatomical assess-
m e n t   o f   t u m o r   b u r d e n ”   (11).  Considering  the  nu-
merous  areas  of  potential  variability  that  must  be 
o v e r c o m e   i n   t h e   a c q u i s i t i o n   a n d   i n t e r p r e t a t i o n   o f  
PET/CT  scans,  this  hesitation  is  understandable. 
Nevertheless,  if  the  attempt  at  standardization 
represented by PERCIST is successful, FDG PET/CT 
m a y   b e   c o n s i d e r e d   a s   a n   a l t e r n a t i v e   s o u r c e   o f   d i s e a s e  
mea s u r e m e n t   i n   f u t u r e   r e v i s i o n s   o f   t h e   R E C I S T   c r i t e-
ria. Functional imaging criteria can also be considered 
for use in conjunction with anatomic criteria such as 
RECIST or MDA (Table 4). 
 
Table 3 Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 
Response category  Criteria 
Complete metabolic response  Normalization of all lesions (target and nontarget) to SUL less than mean liver SUL and 
equal to normal surrounding tissue SUL 
Verification with follow-up study in 1 month if anatomic criteria indicate disease progres-
sion 
 
Partial metabolic response  > 30% decrease in SUL peak; minimum 0.8 unit decrease*  
Verification with follow-up study if anatomic criteria indicate disease progression  
Progressive metabolic disease  > 30% increase in SUL peak; minimum 0.8 unit increase in SUL peak* 
> 75% increase in TLG of the 5 most active lesions 
Visible increase in extent of FDG uptake 
New lesions 
Verification with follow-up study if anatomic criteria indicate complete or partial response 
Stable metabolic disease  Does not meet other criteria 
*Primary outcome determination is measured on the single most active lesion on each scan (not necessarily the same lesion). Secondary 
outcome determination is the summed activity of up to 5 most intense lesions (no more than 2 lesions per organ).  
Abbreviations: SUL, standardized uptake value using lean body mass; TLG, total lesion glycolysis. 
Table modified from Wahl et al. (27). 
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Table 4. Comparison of RECIST, MDA and PERCIST 
  RECIST  MDA criteria  PERCIST 
Characteristics  Anatomic response criteria for soft tissue 
metastases 
Anatomic response criteria for bone me-
tastases 
Functional response criteria re-
flecting tumor metabolism 
Advantages  Common use allows direct comparison of 
the results of different studies 
- Allows the response of the majority of 
bone metastases to be factored into the-
rapeutic response 
Allows response determination 
regardless of the location of the 
metastasis 
- Provides response criteria for patients 
with bone-only disease 
Disadvantages  - Limited to “measurable” soft tissue metas-
tases or unequivocal progression of unmea-
surable disease 
Limited to bone metastases  Limited to FDG avid metastases 
All criteria are subject to minimum lesion size limitations and PERCIST is also subject to minimum FDG uptake limitations. 
 
 
 
Figure 10. Metabolic response according to the PERCIST criteria in the absence of anatomic response. (a) The CT portion 
of an FDG PET/CT scan in a patient with lung cancer demonstrates a lytic metastasis in the left femoral head. (b) The CT 
f r o m   a   P E T / C T   s c a n   2   m o n t h s   l a t e r   d e m o n s t r a t e s   n o   a n a t o m i c   c h a n g e .   (c, d) The standardized uptake value corrected for 
lean body mass (SUL) peak (average SUL in a 1-cm
3 region of interest centered at the most active part of each tumor) 
changes from (c) 19.8 to (d) 12.9, representing a 35% decrease that satisfies the minimal requirements for partial response 
( >   3 0 % )   a c c o r d i n g   t o   P E R C I S T .   A s s e s s m e n t   o f   t u m o r   m e t a b o l i s m   a l l o w e d   t h e r a p e u t i c   r e s p o n s e   t o   b e   m e a s u r e d   i n   t h e  
absence of any other indication of change.  Journal of Cancer 2010, 1 
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Conclusion 
The MDA criteria can allow more bone lesions to 
be  considered  measurable  disease  than  does  the 
RECIST 1.1 system by allowing physical measurement 
of  well-defined bone lesions regardless of soft tissue 
extension, by allowing regimented subjective assess-
ment of ill-defined lesions, and by taking into account 
characteristic behaviors such as the development of 
healing sclerosis. Metabolic imaging criteria can allow 
bone  metastases  to  be  measured  in  the  absence  of 
a n a t o m i c   c h a n g e   b y   a s s e s s i n g   t u m o r   m e t a b o l i s m .  
R e s p o n s e   c r i t e r i a   a r e   o f   c r u c i a l   i m p o r t a n c e   t o   t h e   c a r e  
of many cancer patients, a n d   t h e   t u m o r   r e s p o n s e   a s-
sessment  of  bone  metastases  is  assuming  a  greater 
role  in  therapeutic  management.  Knowledge  of  the 
fundamental  concepts  of  tumor  response  criteria 
(anatomic, bone, and functional) and the appearance 
o f   b o n e   m e t a s t a s e s   a s   t h e y   r e s p o n d   t o   t r e a t m e n t   o r  
progress can aid in the interpretation of studies in a 
m a n n e r   t h a t   w i l l   r e n d e r   t h e m   o f   o p t i m a l   v a l u e   t o   t he 
patient and clinician.  
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